Ignat Drozdov
King's College London
Internal medicineEndocrinologyPathologyOncologyTranscriptomeProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyRadionuclide therapyGene clusterSecretionCancer researchComputational biologyMedicineBiomarker (medicine)Chromogranin ABiologyGastroenterologyCell biology
147Publications
37H-index
5,558Citations
Publications 146
Newest
#1Mark KiddH-Index: 5
#2Ignat DrozdovH-Index: 37
Last. Irvin M Modlin (Yale University)H-Index: 3
view all 9 authors...
BACKGROUND: Multigene-based PCR tests are time-consuming and limiting aspects of the protocol include increased risk of operator-based variation. In addition, such protocols are complex to transfer and reproduce between laboratories. AIMS: Evaluate the clinical utility of a pre-spotted PCR plate (PSP) for a novel multigene (n = 51) blood-based gene expression diagnostic assay for neuroendocrine tumors (NETs). METHODS: A pilot study (n = 44; 8 controls and 36 NETs) was undertaken to compare CQ, n...
Source
#1Benjamin SzubertH-Index: 2
#3Claudia Monaco (University of Oxford)H-Index: 49
Last. Ignat DrozdovH-Index: 37
view all 4 authors...
Single-cell technologies offer an unprecedented opportunity to effectively characterize cellular heterogeneity in health and disease. Nevertheless, visualisation and interpretation of these multi-dimensional datasets remains a challenge. We present a novel framework, ivis, for dimensionality reduction of single-cell expression data. ivis utilizes a siamese neural network architecture that is trained using a novel triplet loss function. Results on simulated and real datasets demonstrate that ivis...
Source
#1Lisa BodeiH-Index: 3
#2Mark KiddH-Index: 4
Last. Irvin M. ModlinH-Index: 11
view all 12 authors...
Source
#1Irvin M. ModlinH-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
Source
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Kyung-Min ChungH-Index: 5
view all 7 authors...
: The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold mo...
Source
#1Cansu Guney GencH-Index: 4
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 9 authors...
Background: Recurrence of pancreatic neuroendocrine tumors (pNET) after surgery is common. Strategies to detect recurrence have limitations. We investigated the role of clinical criteria and the multigene polymerase chain reaction–based NETest during post-operative follow-up of pNET. Methods: We studied 3 groups of resections: R0 with no recurrence (n = 11), R0 with recurrence (n = 12), and R1 with no recurrence (n = 12). NETest levels (>40%) were compared with chromogranin A (CgA) and clinicopa...
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark Kidd (Yale University)H-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 12 authors...
4101Background: PRRT uses somatostatin receptor (SSR) expression on neuroendocrine tumors (NET) to deliver radiotherapy. Pretreatment patient stratification for response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ). This study validates the clinical utility for PRRT. Methods: Development and validation was undertaken in 3 independent 177Lu-PRRT-cohorts. Specificity and prognostic value was tested in two somatos...
Source
#1Pier Luigi Filosso (UNITO: University of Turin)H-Index: 38
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 24 authors...
OBJECTIVES: The management of bronchopulmonary neuroendocrine tumours (BPNETs) is difficult, since imaging, histology and biomarkers have a limited value in diagnosis, predicting outcome and defining therapeutic efficacy. We evaluated a NET multigene blood test (NETest) to diagnose BPNETs, assess disease status and evaluate surgical resection. METHODS: (i) Diagnostic cohort: BP carcinoids (n = 118)-typical carcinoid, n = 67 and atypical carcinoid, n = 51; other lung NEN (large-cell neuroendocrin...
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 12 authors...
Background Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine individual PRRT response remains a key unmet need. NET transcript expression in blood integrated with tumor grade provides a PRRT predictive quotient (PPQ) which stratifies PRRT “responders” from “non...
Source
#1Martin SchrederH-Index: 18
Last. K. Martin KortümH-Index: 14
view all 8 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.